


ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250

**ASX RELEASE**

1 October 2024

Notice under ASX Listing Rule 3.10A

Arovella Therapeutics Limited ACN 090 987 250 (**ALA** or **Company**), hereby advises pursuant to ASX Listing Rule 3.10A that 4,347,826 Ordinary Shares are due to be released from voluntary escrow on **24 October 2024**. These Ordinary Shares were issued for the upfront fee to Sparx Group per the licensing agreement announced 12 Oct 2023.

Details of the securities to be released from voluntary escrow are as follows:

Class / description	Ordinary Shares (Shares)
ASX code	ALA
Date of issue	25 October 2023
Number issued	4,347,826

Tim Luscombe
Company Secretary

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α -GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **α GalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com